Background: Breast cancer (BRCA) ranks as a leading cause of cancer death in women worldwide. Glucose metabolism is a noticeable characteristic of the occurrence of malignant tumors. In this study, we aimed to construct a novel glycometabolism-related gene (GRG) signature to predict overall survival (OS), immune infiltration and therapeutic response in BRCA patients.Materials and methods: The mRNA sequencing and corresponding clinical data of BRCA patients were obtained from public cohorts. Lasso regression was applied to establish a GRG signature. The immune infiltration was evaluated with the ESTIMATE and CIBERSORT algorithms. The drug sensitivity was estimated using the value of IC50, and further forecasted the therapeutic response of each patient. The candidate target was selected in Cytoscape. A nomogram was constructed via the R package of “rms”.Results: We constructed a six-GRG signature based on CACNA1H, CHPF, IRS2, NT5E, SDC1 and ATP6AP1, and the high-risk patients were correlated with poorer OS (P = 2.515 × 10−7). M2 macrophage infiltration was considerably superior in high-risk patients, and CD8+ T cell infiltration was significantly higher in low-risk patients. Additionally, the high-risk group was more sensitive to Lapatinib. Fortunately, SDC1 was recognized as candidate target and patients had a better OS in the low-SDC1 group. A nomogram integrating the GRG signature was developed, and calibration curves were consistent between the actual and predicted OS.Conclusions: We identified a novel GRG signature complementing the present understanding of the targeted therapy and immune biomarker in breast cancer. The GRGs may provide fresh insights for individualized management of BRCA patients.
Ferroptosis is a relatively new form of programmed cell death, which can enhance the efficacy of tumor immunotherapy by regulating the tumor microenvironment (TME). In the face of the dilemma of a great difference in the efficacy of immunotherapy for gastric cancer (GC) patients, the exploration of ferroptosis may assist us in predicting immunotherapy efficacy prior to treatment. The potential role of ferroptosis in TME still needs further elucidation. Based on ferroptosis-related genes (FRGs), we systematically evaluated ferroptosis molecular subtypes in gastric cancer. Additionally, the association between these molecular subtypes and the characteristics of TME was examined. A ferroptosis score was constructed to further explore the predictive efficacy of ferroptosis on the immunotherapy response in gastric cancer. There were also 32 other cancers that were evaluated. Three molecular subtypes of ferroptosis in gastric cancer were identified. The three immunophenotypes of tumor immune inflamed, immune excluded, as well as immune desert were mostly in agreement with the TME features of these three subtypes. The individual tumor genetic variation, TME characteristics, immunotherapy response, and prognosis could be assessed by a ferroptosis score. High ferroptosis scores in gastric cancer suggest stromal activation and immunosuppression. It is noted that tumors with a low ferroptosis score are characterized by extensive tumor mutations as well as an immune activation, which are associated with an enhanced immunotherapy response and an improved prognosis. This study reveals that ferroptosis plays an integral role in the regulation of the tumor immune microenvironment. The ferroptosis score may serve as an independent prognostic factor for GC and will deepen our understanding of the TME infiltration mechanisms as well as lead to more rational immunotherapy regimens.
9 April 2025 in World Journal of Surgical Oncology
The choice of treatment options for recurrent advanced ovarian cancer is very important. However, the most effective treatment options remain unclear. We searched the PubMed, Web of Science, and Cochrane Library databases and the proceedings of the last 5 years of several meetings on ovarian cancer according to the inclusion and exclusion criteria. Randomized controlled trials (RCTs) of recurrent treatment for advanced ovarian cancer with progression-free survival (PFS) were reticulated network meta-analyzed. RCTs were also analyzed for Grades 3 or higher drug-associated adverse events. We included 24 RCTs involving 6,250 patients with advanced recurrent ovarian cancer and a total of 10 treatment regimens. Our network meta-analysis revealed that the PARP plus anti-angiogenic regimen (Surface Under the Cumulative Ranking Curve, SUCRA 95.26%) outperformed eight other regimens and demonstrated a significant improvement in patient survival. The double immunotherapy plus chemotherapy regimen (SUCRA: 87.24%) showed strong efficacy. Additionally, the anti-angiogenic plus chemotherapy regimens (SUCRA: 60.14%), single anti-angiogenic regimens (SUCRA: 52.3%), and poly ADP-ribose polymerase regimens (SUCRA: 61.82%) demonstrated similar efficacy. Interestingly, immunotherapy plus chemotherapy regimens (SUCRA: 31.61%) showed a significant improvement compared to chemotherapy regimens, and double immunotherapy regimens (SUCRA: 36.49%) also demonstrated strong efficacy. However, single immunotherapy regimens (SUCRA: 8.53%) demonstrated limited efficacy. Finally, we found that the incidence of grade 3 or higher adverse reactions was low and manageable for all treatment options. This meta-analysis showed that the PARP plus anti-angiogenic regimen is superior to the other nine regimens in treating patients with advanced recurrent ovarian cancer and can significantly improve their survival. Our results show that the anti-angiogenic plus CT, single-agent anti-angiogenic, and single-agent PARP regimens have similar efficacies; therefore, clinical treatment plans can be adjusted based on the differences in side effects among the three regimens. The double immunotherapy regimen demonstrated superior efficacy compared to the single immunotherapy regimen, particularly in terms of patient survival. These results may offer new therapeutic options for patients with advanced recurrent ovarian cancer, particularly through the use of immunotherapy. PROSPERO (ID CRD420251007476) https://www.crd.york.ac.uk/PROSPERO/view/CRD420251007476 .
Background: High-grade serous ovarian cancer (HGSOC) poses significant treatment challenges due to frequent recurrence and resistance to conventional therapies. Combination of anlotinib with immunotherapy have showed promise in various cancers, but its impact on HGSOC remains to be fully elucidated.Methods: A retrospective analysis was performed on 36 HGSOC patients treated with anlotinib-based therapies, including both monotherapy and combination treatment with anti-PD-L1/anti-PD-1 antibody (aPD-L1/aPD-1). Peripheral blood mononuclear cell-derived patient-derived xenograft (PBMC-PDX) model was established from drug-resistant recurrent HGSOC patient-derived tumor cells, and single-cell RNA sequencing (scRNA-seq) was conducted to dissect the TME following treatment with anlotinib, anlotinib + aPD-L1 and anlotinib + aPD-1.Results: Clinical analysis revealed a disease control rate (DCR) of 71.43% for anlotinib monotherapy, which improved to 100% when combined with aPD-L1/aPD-1. In PBMC-PDX models, treatment evaluation showed that anlotinib decreased tumor volume, an effect further enhanced by its combination with aPD-L1. scRNA-seq analysis demonstrated that anlotinib reduced the proportions of myofibroblastic cancer-associated fibroblasts and ESM1+ endothelial cells, resulting in decreased angiogenesis. The combination of anlotinib and aPD-L1 further amplified these effects, promoting CD8+ T cell infiltration and reversing T cell exhaustion, whereas anlotinib + aPD-1 showed limited efficacy in this regard. Additionally, anlotinib + immunotherapy induced a shift toward M1 polarization of myeloid cells, enhanced anti-tumor activity, and inhibited immune escape. Cell-cell communication analysis revealed reduced APP-CD74 signaling and increased CD99-CD99 signaling, which might contribute to immune activation.Conclusion: The combination of anlotinib and aPD-L1 effectively modulates the HGSOC tumor microenvironment by inhibiting angiogenesis, enhancing immune infiltration, and reversing T cell exhaustion.
There has been an increasing incidence of breast cancer around the world in recent years. As a burgeoning model of diagnosis and treatment, precision medicine has become a new trend in breast cancer management. Dysregulated glycometabolism is well established as a tumor feature. SDC1 is a glycometabolism-related gene and participates in the progression, metastasis, resistance and recurrence of malignant tumors. SDC1 promotes the development of breast cancer by disturbing tumor stem cell phenotypes, the cell cycle and apoptosis, and then modulates macrophage migration, epithelial-mesenchymal transformation, angiogenesis and the tumor-bone microenvironment. We summarized the recent advances regarding the role of SDC1 in the mechanism driving the occurrence of breast cancer, and evaluated its potential therapeutic contributions.